Bavarian Biotech Report 2011/2012 (7MB) - Bio M

multimmune GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSContact:Dr. Claus BotzlerArnulfstr. 197D-80634 MünchenPhone: +49 (0) 89 4520-7707Fax: +49 (0) 89 4140-4299E-Mail: info@multimmune.deInternet: www.multimmune.deKeywords: Drug Development, Clinical Diagnostics, Antibody, Cell Therapy,Vaccines, Oncologymultimmune is a biopharmaceutical company dedicated to the discoveryand development of new products for the treatment of cancer. The companyfocuses on the development of drug candidates to treat heat shock protein70 (Hsp70) positive tumors, as surface-bound Hsp70 is a tumor-specific markerexpressed on about 50-75% of various cancer entities, e.g. lung, breast,colon, pancreas.Currently, four approaches are being explored to destroy cancer cells: (1) byextracorporal activation of Natural Killer (NK) cells with a synthetic peptide(ready to go into phase II), (2) by using an antibody against Hsp70 (preclinical),(3) by inducing tumor specific apoptosis with a recombinant human serineprotease(preclinical), (4) by direct infusion of an Hsp70 peptide (preclinical).Contact:Dr. Josef ReisingerJosef-Engert-Str. 13D-93053 RegensburgPhone: +49 (0) 941 63086-49Fax: +49 (0) 941 63086-48E-Mail:josef.reisinger@multi-service-monitoring.deInternet: www.multi-service-monitoring.demulti-service-monitoringCROKeywords: Drug Developmentmulti-service-monitoring (in the BioPark, founded in 2003, 5 employees) is aclinical research organisation (CRO) that is specialised in monitoring of noncommercialclinical trials and medical clinical trials with devices. All tasksare carried out in accordance with the appropriate national regulations andthe international guidelines ICH/GCP.MWM Biomodels GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Drug Development, Pharmacokinetics, Transgenic Animals,Cardiovascular Diseases, Diabetics, Respiratory DiseasesContact:Dr. Christian SimmetHauptstr. 41D-84184 TiefenbachPhone: +49 (0) 8709 9229-664Fax: +49 (0) 8709 9229-82664E-Mail: csimmet@minitube.deMWM Biomodels GmbH is a spin-off company of the LMU Munich andMinitube, specialized in the development and characterization of transgeniclarge animal models for biomedical research. Current projects are focusedon genetically modified pigs for xenotransplantation as well as transgenicpig models of diabetes mellitus, muscular dystrophy and immunodeficiency.MWM Biomodels offers support starting from the design of a project, thedevelopment of expression and targeting vectors, the generation ofgenetically modified large animals, their phenotypic characterization andthe performance of preclinical studies.90